Themis Medicare sees a credit rating action

The clearest threshold breach was interest coverage. CARE’s negative sensitivity threshold is an interest coverage ratio below 1.5x on a sustained basis; the rationale reported 0.26x in FY26 versus 5.04x in FY25, with coverage remaining distressed in Q1 FY27 because of the operating loss. ^{[1] [2]}

Debt-to-EBITDA was not the ratio CARE quantified in this rationale. The agency used total debt to gross cash accruals (TD/GCA), which rose to 10.79x, alongside the collapse in interest coverage. ^[2]

The working-capital deterioration was also broad-based: inventory days rose to 95 from 86, collection days to 188 from 160, and the operating cycle to 230 from 196 days. ^[2] Liquidity was further pressured by 74.48% average working-capital utilisation and negative FY26 operating cash flow of Rs 7.09 Crores. ^[2]

One basis caveat matters: CARE’s consolidated ratio table shows FY26 interest coverage of -0.71x versus 4.05x in FY25, while the narrative ratio discussion gives 0.26x versus 5.04x. ^{[4] [2]} The directional conclusion is unchanged: coverage fell decisively below CARE’s 1.5x negative sensitivity level.

No exact quantum is disclosed for floating-rate debt or debt due for refinancing within the next 12 months, and neither the company nor CARE quantifies the downgrade’s incremental impact on interest expense.

• The latest consolidated total debt was Rs 100.09 Crores in Q1 FY27 ^[5]. This is the gross debt balance, but the disclosure does not split it between fixed- and floating-rate borrowings or provide a maturity/refinancing schedule.
• CARE’s rating table lists Rs 77.39 Crores of long-term bank facilities and Rs 48.50 Crores of short-term bank facilities ^[6]. Their derived aggregate is Rs 125.89 Crores, but this is the rated-facility quantum, not necessarily debt outstanding and not evidence that the amount is floating-rate or due for refinancing within 12 months.
• The downgrade materials do not provide a sensitivity such as “a 100-bps increase would add Rs X Crores to annual finance costs.” The available data only shows that finance costs rose 20.6% YoY and 10.4% QoQ in Q1 FY27 ^[7], while consolidated interest coverage deteriorated to -0.71x in FY26 from 4.05x in FY25 and was reported as not meaningful in Q1 FY27 ^[4].

Implication: the credit downgrade creates potential refinancing and borrowing-cost risk, but the incremental effect on the interest-expense line cannot be calculated from the disclosure because the floating-rate exposure, repricing assumptions, refinancing dates and revised interest spreads are not reported.

The liquidity picture is stretched on a cash-versus-debt basis, even though the headline current ratio remains comfortable. The latest consolidated balance-sheet figures available for March 31, 2026 show cash and equivalents of Rs 4.54 Crores against current borrowings of Rs 78.23 Crores. On that basis, cash covered only about 5.80% of current borrowings, leaving approximately Rs 73.69 Crores before considering receivables, inventory and other current assets. These figures are derived from the reported cash and current-borrowing balances. ^{[8] [9]}

Reconciliation with CARE’s assessment

• CARE reported free cash and bank balances of Rs 5.75 Crores as of March 31, 2026, somewhat above the Rs 4.54 Crores cash-and-equivalents figure in the structured balance sheet. The two figures are not labelled identically, so the difference should be treated as a classification or scope mismatch rather than as a confirmed change in cash. ^[2]
• CARE’s 1.82x current ratio and 1.33x quick ratio are consistent with the latest reported current ratio of approximately 1.84x. ^{[2] [10]}
• The apparent contrast—comfortable current ratio but low cash coverage—is explained by the composition of current assets. Liquidity depends heavily on collecting receivables and monetising inventory rather than on immediately available cash. CARE described the business as highly working-capital intensive, with a 315-day gross current-assets period, 188-day collection period, and 95-day inventory period in FY26. ^[2]
• CARE therefore classified liquidity as stretched, citing negative FY26 operating cash flow of Rs 7.09 Crores, inadequate internal cash accruals relative to debt repayments, and reliance on investment-sale proceeds for support. ^[2] The reported sale of part of the Gujarat Themis Biosyn investment provided a stated liquidity cushion of Rs 100 Crores during Q1 FY27, but this was an exceptional funding source rather than recurring operating cash generation. ^[1]

The Rs 48.50 Crores of short-term bank facilities in CARE’s rating table should not be used as the short-term debt outstanding: it is the rated facility amount, whereas Rs 78.23 Crores is the balance-sheet current-borrowing measure. ^{[1] [9]}

Working-capital limit utilization

There has been a clear increase or elevated use of working-capital funding:

• CARE reported average maximum utilization of working-capital limits at 74.48% for the 12 months ended July 2026. ^[2]
• The agency also stated that utilization was higher in FY26, alongside additional term loans and higher LC-backed acceptances. ^[3]

The report does not provide a prior comparable utilization percentage, so the precise change in percentage points cannot be calculated. Also, the cited 74.48% is an average of maximum utilization, not average daily utilization. The evidence nevertheless supports CARE’s conclusion that working-capital dependence has increased and is a central liquidity risk.